/ Cadila Healthcare Gains Over 1% On USFDA Nod For Doxazosin Tablets ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Tuesday, 11 July 2017

The stock of Cadila Healthcare gained over 1% during Tuesday’s trade on the BSE, driven by the tentative approval from the USFDA for Lurasidone Hydrochloride tablets.

Lurasidone is a generic version of Latuda that is used to treat schizophrenia.

Cadila Healthcare, on July 8, received approval from the US Food and Drug Administration (USFDA) to market Doxazosin tablets. It is a selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia.

Cadila Healthcare was trading at Rs 523.55, up by Rs 5.40 or 1.04% as at 1144 hours on Tuesday, on the BSE. The stock had hit an intraday high of Rs 524.70.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717